Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...

South San Francisco biotech Pionyr was sold two years ago. Now three of its leaders want to test a trio of drugs beyond ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...